Daa Pangenotypic Epclusa denied as non-formulary by Humana?

Humana's specific coverage criteria for daa pangenotypic epclusa are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Issued a Non-Formulary Denial for Epclusa

Epclusa (sofosbuvir/velpatasvir) may not appear on Humana's preferred formulary tier, or it may be placed on a tier that requires prior authorization or a formulary exception. A non-formulary denial means the plan's pharmacy benefit structure, not a clinical judgment about the drug's effectiveness, is the primary obstacle. Formulary placement can differ between Humana commercial plans and Medicare Part D plans, so the appeal path varies slightly.

Formulary exception appeals are explicitly recognized under federal law and Humana's own coverage framework. When a patient's prescriber documents that the formulary alternative is clinically inappropriate — contraindicated, previously tried and failed, or likely to be ineffective given the patient's hepatitis C genotype or clinical profile — the plan must consider approving the non-formulary drug.

## Federal Appeal Framework

• ACA Section 2719 / external review: Non-grandfathered commercial plans must offer independent external review after internal appeals are exhausted. The standard window is approximately four months from denial; expedited review (roughly 72 hours) is available for urgent cases. Check your Explanation of Benefits for the exact deadline.
• Medicare Part D (if applicable): Humana Part D plans have a separate formulary exception and coverage determination process governed by CMS rules, with its own appeal tiers (redetermination, reconsideration, ALJ hearing). Use the timeframes on your Medicare denial notice.
• ERISA Section 503: Employer-sponsored commercial plans must provide a full-and-fair internal review.

## Concrete Appeal Steps and Timeline

1. Obtain Humana's current formulary for your specific plan year — identify whether a formulary exception pathway exists and what documentation is required. 2. Confirm which formulary-preferred hepatitis C alternatives Humana lists and why they are not appropriate for this patient. 3. File a formulary exception request with the prescriber's letter attached; this may resolve the issue before a formal appeal is needed. 4. If the exception is denied, file a Level 1 internal appeal within the plan-stated deadline and request external review if upheld.

## Documentation to Gather

• Diagnosis confirmation: Hepatitis C genotype, viral load, and fibrosis/cirrhosis staging.
• Formulary-alternative failure or contraindication: Chart or prescriber documentation explaining why each listed formulary alternative is clinically inappropriate for this patient — for example, prior treatment failure, genotype mismatch, or a clinical factor described in the Epclusa prescribing label.
• Prior-treatment history: Dates and outcomes of any prior DAA or interferon regimens.
• Prescriber medical-necessity letter: Attestation that Epclusa is the medically necessary choice and that the formulary alternative cannot achieve the same clinical outcome for this patient.

## Criteria-Mapping Structure

Obtain (a) the FDA-approved prescribing information for Epclusa and (b) Humana's formulary exception criteria for hepatitis C agents. For each criterion, document the corresponding chart finding. A clear mapping that explains why the formulary alternative is insufficient — rather than simply asserting that Epclusa is preferred — is the most persuasive structure for a formulary exception appeal.